John Alam’s Post

Major publication in Nature Communications with our drug that contains both preclinical/scientific and clinical trial data. Puts together the many pieces of the puzzle we have been working over the past few years at EIP, and provides foundation for taking our drug into confirmatory clinical trials in patients with dementia with Lewy bodies. Read the publication here: https://rdcu.be/cV0Ro

Joshua Boger

Founder - Vertex Pharmaceuticals, Chair of the Board - Alkeus Pharmaceuticals, Chair of the Board - Cervomed, Inc. (CRVO)

2y

This is a major paper that should shake the foundations of the field. This is the way science is supposed to be done: sufficientLy iconoclastic to be real progress and meticulous intellectual and experimental integrity to back it up.

Alpna Seth, PhD

Board Member, CEO, Biotech Pharma Executive, Life Sciences Technologies

2y

Congratulations John!

Like
Reply
Lindsey White

Senior Manager, Bain & Company

2y

Amazing news, John! Wishing you all the best!

Like
Reply
India Wardrop

Venture Partner, Impact Entrepreneur, Growth Strategist

2y

Congratulations John, Fanastic to see this.

Like
Reply
Leslie Williams DVM, MPH, Diplomate ACVAA

Principal, L. Williams Pharmacovigilance Consulting, LLC

2y

Congratulations John!

Like
Reply

Congratulations John and team. Great to hear about the progress you are making for such a good cause

Like
Reply
Varun Garg

VP, Clinical Pharmacology at PureTech Health

2y

Congratulations John!

Rob Perez

Senior Advisor, General Atlantic, Founder and Chairman, Life Science Cares, Co-Founder, BLOC:Biopharma Leaders of Color

2y

Congrats John Alam and Sylvie Gregoire!

Like
Reply
Michele Belansky

Head of Global Internal Communications @ CyberArk | Strategic Communications and Corporate Affairs Leader | Driving Employee Experience and Engagement

2y

John, congratulations to you and the team

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics